home / stock / nrx:cc / nrx:cc news

NRX:CC News and Press, NurExone Biologic Inc. From 02/20/24

Stock Information
Company Name: NurExone Biologic Inc.
Stock Symbol: NRX:CC
Market: TSXVC
Website: nurexone.com
Menu
NRX:CC NRX:CC Quote NRX:CC Short NRX:CC News NRX:CC Articles NRX:CC Message Board
Get NRX:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
NRX:CC - NurExone's Intellectual Property Portfolio Expands

TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serv...
NRX:CC - NurExone Launches Licensing Efforts for ExoTherapy Platform

TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for cre...

NRX:CC - Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant

TORONTO and HAIFA, Israel, Feb. 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), known as "NurExone," is pleased to announce the initiation of the Orphan Drug Designation process with the European Medicines Agency (EMA) for its groundbreaking ExoPTEN product, cu...

NRX:CC - Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX)

(NewsDirect) Investors eyeing dynamic opportunities in healthcare should take note of the burgeoning growth anticipated in the spinal cord injury market. Projections for robust advancements, driven by enhanced diagnosis and increased global healthcare spending, signal a lucrative trajectory f...
NRX:CC - NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market

TORONTO and HAIFA, Israel, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal c...

NRX:CC - NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million

TORONTO and HAIFA, Israel , Jan. 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal ...

NRX:CC - NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration

TORONTO and HAIFA, Israel, Nov. 29, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”) has recently unveiled laboratory tests of its secondary two proprietary sequences, representing a significant advancement in...
NRX:CC - NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, released a corporate update and reported financial results for the quarter ended Septem...

NRX:CC - Expected Canadian Company Earnings on Thursday, November 23rd, 2023

Green Impact Partners Inc. (GIP:CA) is expected to report $-0.06 for Q3 2023 Valdor Technology International Inc. (VTI:CA) is expected to report for Q1 2024 Lycos Energy Inc. (LCX:CA) is expected to report for Q1 2024 49 North Resources Inc. (FNR:CA) is expected to report for quarter ...

NRX:CC - Expected earnings - NurExone Biologic Inc.

NurExone Biologic Inc. (NRX:CA) is expected to report $-0.03 for Q3 2023
Previous 10 Next 10